Karolinska Development Ab Quote - 0P3C

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

6.50

Bid

0.00

Ask

0.00

Volume

0.00

0.00 Day's Range 0.00

6.50 52 Week Range 6.50

Market Cap

1.739B

Previous Close

6.50

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

358

Shares Outstanding

267,522,000

Dividend Yield

PE Ratio

323.38

Earnings Per Share (EPS)

0.02

Revenue

2.01M

Net Profit

5.39M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.karolinskadevelopment.com

Headquarters

Solna, Swe

Founded

Karolinska Development Ab is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker 0P3C. The last closing price for Karolinska Development Ab was SEK6.50. Over the last year, Karolinska Development Ab shares have traded in a share price range of SEK 6.50 to SEK 6.50.

Karolinska Development Ab currently has 267,522,000 shares outstanding. The market capitalization of Karolinska Development Ab is SEK1.74 billion. Karolinska Development Ab has a price to earnings ratio (PE ratio) of 323.38.

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities STOCKHOLM, SWEDEN – January 30, 2025. Karolinska...

Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01

Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01 STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq...

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone

Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB...

Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman

Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the...

Karolinska Development’s Chairman of the Board resigns at his own request

Karolinska Development’s Chairman of the Board resigns at his own request STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the...

Karolinska Development divests 4,6 million shares in portfolio company OssDsign

Karolinska Development divests 4,6 million shares in portfolio company OssDsign STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares...

Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia STOCKHOLM, SWEDEN – December 9...

Karolinska Development implements organizational changes for more efficient portfolio management

Karolinska Development implements organizational changes for more efficient portfolio management STOCKHOLM, SWEDEN – December 2, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today...

Karolinska Development's portfolio company Modus Therapeutics secures bridge financing

Karolinska Development's portfolio company Modus Therapeutics secures bridge financing STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces...

Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	6.5	6.5	6.5	4080	6.5	DE
4	6.5	6.5	6.5	1020	6.5	DE
12	6.5	6.5	6.5	358	6.5	DE
26	6.5	6.5	6.5	158	6.5	DE
52	6.5	6.5	6.5	223	6.5	DE
156	6.5	6.5	6.5	454	6.5	DE
260	6.5	6.5	6.5	641	6.5	DE

0P3C - Frequently Asked Questions (FAQ)

What is the current Karolinska Development Ab share price?

The current share price of Karolinska Development Ab is SEK 6.50

How many Karolinska Development Ab shares are in issue?

Karolinska Development Ab has 267,522,000 shares in issue

What is the market cap of Karolinska Development Ab?

The market capitalisation of Karolinska Development Ab is SEK 1.74B

What is the 1 year trading range for Karolinska Development Ab share price?

Karolinska Development Ab has traded in the range of SEK 6.50 to SEK 6.50 during the past year

What is the PE ratio of Karolinska Development Ab?

The price to earnings ratio of Karolinska Development Ab is 323.38

What is the cash to sales ratio of Karolinska Development Ab?

The cash to sales ratio of Karolinska Development Ab is 866.67

What is the reporting currency for Karolinska Development Ab?

Karolinska Development Ab reports financial results in SEK

What is the latest annual turnover for Karolinska Development Ab?

The latest annual turnover of Karolinska Development Ab is SEK 2.01M

What is the latest annual profit for Karolinska Development Ab?

The latest annual profit of Karolinska Development Ab is SEK 5.39M

What is the registered address of Karolinska Development Ab?

The registered address for Karolinska Development Ab is TOMTEBODAVAGEN 23 A, SOLNA, SE 171 65

What is the Karolinska Development Ab website address?

The website address for Karolinska Development Ab is www.karolinskadevelopment.com

Which industry sector does Karolinska Development Ab operate in?

Karolinska Development Ab operates in the COML PHYSICAL, BIOLOGCL RESH sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ASTAscent Resources Plc	1.90p (100.00%)	591.55k
NTQEnteq Technologies Plc	2.85p (58.33%)	17.97M
THRUThruvision Group Plc	3.25p (30.00%)	307.66k
IMMImmupharma Plc	4.98p (27.69%)	14.75M
GEXGeorgina Energy Plc	6.375p (24.39%)	5.16M
BELLBelluscura Plc	1.875p (-71.15%)	13.68M
APQApq Global Limited	2.00p (-69.23%)	60.87k
IOMIomart Group Plc	45.40p (-23.57%)	1.76M
SYMESupply@me Capital Plc	0.002p (-20.00%)	736.23M
PRMProteome Sciences Plc	3.50p (-17.45%)	50.06k
SYMESupply@me Capital Plc	0.002p (-20.00%)	736.23M
ORCPOracle Power Plc	0.017p (-14.14%)	523.64M
CPAICapai Plc	0.0475p (7.95%)	355.25M
NTVONativo Resources Plc	0.0017p (0.00%)	347.62M
MSMNMosman Oil And Gas Limited	0.04p (2.56%)	263.67M